← Back to Search

Immunotoxin

Immunotoxin Therapy for Brain Cancer

Phase 1

Waitlist Available

Research Sponsored by Xenova Biomedix

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 5 to 18

Performance status Karnofsky 60-100% OR Lansky Play 50-100%

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying a glioblastoma and anaplastic astrocytoma immunotoxin called C235-IgG.

Who is the study for?

This trial is for children aged 5-18 with progressive or recurrent glioblastoma multiforme or anaplastic astrocytoma who've had surgery and radiation. They must be relatively healthy, not pregnant, and without severe infections or conditions that would interfere with anesthesia.Check my eligibility

What is being tested?

The study tests immunotoxin therapy's ability to target and kill tumor cells while sparing normal ones in children with specific brain tumors. It's a Phase I trial focused on assessing the treatment's effectiveness.See study design

What are the potential side effects?

While the exact side effects are not listed here, immunotoxins can potentially cause allergic reactions, damage to non-cancerous cells leading to various symptoms depending on the affected organs, fatigue, nausea, and may affect blood counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 5 and 18 years old.

Select...

I can do most activities, but may need help.

Select...

My brain tumor is a specific type and size, located in one area.

Select...

My cancer has grown by at least 25% in volume or 15% in area.

Select...

I have had surgery and radiation for my condition.

Select...

My brain scans show no significant swelling or pressure effects.

Select...

My liver function tests are within the required limits.

Select...

I don't have any serious infections or conditions that would stop me from having anesthesia.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

Xenova BiomedixLead Sponsor

1 Previous Clinical Trials

323 Total Patients Enrolled

Patrick Rossi, MDStudy ChairXenova Biomedix

Media Library

Immunotoxin Therapy (Immunotoxin) Clinical Trial Eligibility Overview. Trial Name: NCT00052624 — Phase 1

Brain Tumor Clinical Trial 2023: Immunotoxin Therapy Highlights & Side Effects. Trial Name: NCT00052624 — Phase 1

Immunotoxin Therapy (Immunotoxin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00052624 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an age threshold for participants to be accepted into this trial?

"According to the requirements of this research, potential participants must be between 5 and 18 years old."

Answered by AI

Are there still opportunities for participation in this research project?

"This trial, which was posted on July 1st 2002 and last modified on May 14th 2018 is not currently recruiting. Fortunately, there are numerous other clinical trials actively seeking participants at this time; 566 to be exact."

Answered by AI

Has this therapy been granted formal authorization by the FDA?

"Our team at Power has assigned a score of 1 to the safety profile of this treatment due to it being in Phase 1 and having limited data available on both efficacy and safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

2002. "Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00052624.

All > Anaplastic Ependymoma > Anaplastic Astrocytoma